Cas:22201-45-2 (4-tert-butylbenzoyl) 4-tert-butylbenzoate manufacturer & supplier

Chemical Name:(4-tert-butylbenzoyl) 4-tert-butylbenzoate

CAS.NO:22201-45-2

Synonyms:4-tert-butyl-benzoic acid-anhydride;Benzoic acid,4-(1,1-dimethylethyl)-,anhydride;4-tBu-benzoic anhydride;p-tert-Butylbenzoic acid anhydride;4-tert-butylbenzoyl anhydride;p-tert-Butylbenzoicanhydride;p-t-butyl benzoic acid anhydride;4-tert-Butyl-benzoesaeure-anhydrid;4-(tert-butyl)benzoic anhydride;Benzoicacid,4-(1,1-dimethylethyl)-,anhydride (9CI);Benzoic acid,p-tert-butyl-,anhydride (8CI);Benzoic acid,4-(1,1-dimethylethyl)-,anhydride with 4-(1,1-dimethylethyl)benzoic acid

Molecular Formula:C₂₂H₂₆O₃

Molecular Weight:338.44000

HS Code:2916399090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:455.326ºC at 760 mmHg

Density:1.057g/cm3

Index of Refraction:1.536

PSA:43.37000

Exact Mass:338.18800

LogP:5.27880

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-tert-butyl-benzoic acid-anhydride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzoic acid,4-(1,1-dimethylethyl)-,anhydride with 4-(1,1-dimethylethyl)benzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzoic acid,4-(1,1-dimethylethyl)-,anhydride with 4-(1,1-dimethylethyl)benzoic acid Use and application,4-(tert-butyl)benzoic anhydride technical grade,usp/ep/jp grade.

Related News: Green Valley said it would launch the drug ��very soon�� in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug. (4-tert-butylbenzoyl) 4-tert-butylbenzoate manufacturer Green Valley said it would launch the drug ��very soon�� in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug. (4-tert-butylbenzoyl) 4-tert-butylbenzoate supplier Microarrays of over 5,500 plasma membrane and secreted protein targets are expressed in human cells. (4-tert-butylbenzoyl) 4-tert-butylbenzoate vendor Microarrays of over 5,500 plasma membrane and secreted protein targets are expressed in human cells. (4-tert-butylbenzoyl) 4-tert-butylbenzoate factory One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively.